ENCell Co., Ltd. (456070.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩4,660 (-0.11%) as of
Key statistics
- Market cap
- 51.27B
- Dividend yield
- 0.00%
- 52-week range
- 4,650.00 – 20,950.00
- Beta
- 0.07
- Revenue (TTM)
- 4.16B
- Profit margin
- 0.00%
- Volume
- 20.10k
About ENCell Co., Ltd.
ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.